The primary objective of this proposal is to elucidate the molecular mechanism governing vascular smooth muscle cell (VSMC) differentiation from neural crest stem cells (NCSCs). Abnormal VSMC differentiation contributes to a number of major cardiovascular disorders including the most prevalent forms of congenital heart disease (CHD). Both in vivo and in vitro studies have demonstrated that TGF- signaling is critical for VSMC differentiation from NCSCs. However, the molecular mechanisms underlying the complex activities of TGF- on this process remain largely unknown. By utilizing in vitro model systems we found that the TGF- downstream intermediate Smad2, but not Smad3, is critical for TGF--induced VSMC differentiation from NCSCs;while Smad3, but not Smad2, is important for VSMC differentiation from mesenchymal- originated (non-NCSC) C3H10T1/2 cells. These findings strongly support the hypothesis that Smad2 acts as an important and specific mediator of TGF- in VSMC differentiation from NCSCs. More importantly, we made the novel observation that Smad2, but not Smad3, is required for VSMC marker gene activation in NCSCs. We also found that myocardin-related transcription factor B (MRTFB) contributes to VSMC specific gene activation in NCSCs. To investigate the mechanism by which TGF- regulates VSMC differentiation from NCSCs, we will focus on two Specific Aims.
In Aim 1, we will study the molecular mechanisms underlying the Smad2 function in VSMC differentiation from NCSCs. We will determine how Smad2 regulates transcriptional activation of VSMC marker genes, and determine if Smad2 interacts with MRTFB in controlling marker gene promoters.
In Aim 2, we will test the hypothesis that Smad2 is essential for VSMC differentiation from NCSCs in vivo, using a neural crest tissue-specific knockout (Wnt1-Cre) mouse. The specificity of Smad2 in NCSCs will be further tested by mutating Smad2 gene in VSMC of non-NCSC origins by using a SM22-Cre mouse. NCSC differentiation is a complex process modulated by multiple factors, including TGF- and its family members. Through a combination of biochemical, molecular, cellular and developmental biological techniques, the function of Smad2 in VSMC differentiation will be thoroughly studied. Accomplishment of the proposed studies will significantly advance our understanding of the molecular mechanism by which TGF- regulates NCSC differentiation to VSMC and contribute to the development of novel therapeutics for the treatment of human cardiovascular diseases including CHD. Moreover, since Smad2 is specific to the VSMC differentiated from NCSC while Smad3 is specific to the VSMC from mesoderm, our studies will likely provide new revenues for drug intervention specifically targeting at diseases that are caused by abnormal function of VSMCs from different origins.
Vascular smooth muscle differentiation is closely related to several major cardiovascular diseases including congenital heart disease. The proposed studies focusing on the function of Smad2 will significantly advance our understanding of the molecular mechanisms governing the smooth muscle differentiation from neural crest cells. The results will shed new light on the pathogenesis of congenital heart disease and a number of genetic diseases such as hereditary hemorrhagic telangiectasia type 1 and type 2, which may ultimately lead to therapeutic intervention.
|Li, Guo-Hua; Luo, Bin; Lv, Yan-Xia et al. (2016) Dual effects of VEGF-B on activating cardiomyocytes and cardiac stem cells to protect the heart against short- and long-term ischemia-reperfusion injury. J Transl Med 14:116|
|Shi, Ning; Chen, Shi-You (2014) Mechanisms simultaneously regulate smooth muscle proliferation and differentiation. J Biomed Res 28:40-6|
|Tang, Rui; Chen, Shi-You (2014) Smooth muscle-specific drug targets for next-generation drug-eluting stent. Expert Rev Cardiovasc Ther 12:21-3|
|Guo, Xia; Stice, Steven L; Boyd, Nolan L et al. (2013) A novel in vitro model system for smooth muscle differentiation from human embryonic stem cell-derived mesenchymal cells. Am J Physiol Cell Physiol 304:C289-98|
|Shi, Ning; Chen, Shi-You (2013) Cell division cycle 7 mediates transforming growth factor-Î²-induced smooth muscle maturation through activation of myocardin gene transcription. J Biol Chem 288:34336-42|
|Cui, Xiao-Bing; Guo, Xia; Chen, Shi-You (2013) Response gene to complement 32 deficiency causes impaired placental angiogenesis in mice. Cardiovasc Res 99:632-9|
|Xie, Wei-Bing; Li, Zuguo; Shi, Ning et al. (2013) Smad2 and myocardin-related transcription factor B cooperatively regulate vascular smooth muscle differentiation from neural crest cells. Circ Res 113:e76-86|
|Tang, Rui; Cui, Xiao-Bing; Wang, Jia-Ning et al. (2013) CTP synthase 1, a smooth muscle-sensitive therapeutic target for effective vascular repair. Arterioscler Thromb Vasc Biol 33:2336-44|
|Zhang, Lei; Wei, Shuang; Tang, Jun-Ming et al. (2013) PEP-1-CAT protects hypoxia/reoxygenation-induced cardiomyocyte apoptosis through multiple sigaling pathways. J Transl Med 11:113|
|Zhang, Lei; Wang, Jia-Ning; Tang, Jun-Ming et al. (2012) VEGF is essential for the growth and migration of human hepatocellular carcinoma cells. Mol Biol Rep 39:5085-93|
Showing the most recent 10 out of 26 publications